Ewelina Weglarz-Tomczak (UvA): Lysosomal protease inhibitors for Alzheimer’s
Ewelina Weglarz-Tomczak (UvA): Novel lysosomal protease inhibitors for the treatment of Alzheimer’s disease
Highly specified proteases are the key regulators in the molecular mechanism of neurodegeneration in Alzheimer’s disease. AI-powered technology developed by NatInLab has led to the discovery of how those proteases are controlled in the human organism. Based on this knowledge, developing novel, highly effective and safe inhibitors of these proteases is possible. The project aims to deliver new agents against Alzheimer’s and possibly other neurodegenerative diseases as the next step. The novel drugs are expected to be curative and show minimal side effects.
Explore other Cases:
Paul Merkus (Amsterdam UMC): BoneMRI of the head
Paul Merkus (Amsterdam UMC): BoneMRI of the head There are many young patients that face deafness and need surgery to be able to hear. Before the surgery, the ENT-surgeon currently needs two scans: an MRI to visualize the soft tissues like nerves, and a CT scan to show the bony structures. However, the CT scanning […]
John van der Kamp and Boris Lancelot (VU): Lentala
John van der Kamp and Boris Lancelot (VU): Rom & Lupa designed by Lentala: school furniture for active sitting Today, children move too little and sit too much, especially a school classrooms. Prolonged passive sitting is a risk factor for poor physical health and low mental well-being. The human body has evolved to move and […]
Imran Avci (VU): COMB-O
Imran Avci (VU): Disposable, ultra-sensitive optical biosensors for early cancer diagnosis (COMB-O) In the last decade, cancer has become a silent pandemic as it is the second leading cause of death globally. Early diagnosis is critical for successful treatment, and therefore we urgently need sensitive, specific and affordable solutions. The development of optical biosensors that […]